Lead Product(s): PXS-6302
Therapeutic Area: Dermatology Product Name: PXS-6302
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Together Australian pharmaceutical and University of Western Australia will test Pharmaxis’s topical discovery, known as PXS-6302, which has shown promising pre-clinical results in restraining the enzymes that play a significant role in the development of scar tissue.